Wednesday, 14 October 2026European Markets

ELKEM, SOLVAC NOM(RETAIL), Another 1 Companies Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(VIANEWS) - ELKEM (ELK.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Basic Materials sector.

Financial Asset Price Forward Dividend Yield Return on Equity
ELKEM (ELK.OL) kr20.56 25.91% 19.37%
SOLVAC NOM(RETAIL) (SOLV.BR) €103.00 5.7% 4.21%
CORTICEIRA AMORIM (COR.LS) €8.92 4.44% 11.55%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ELKEM (ELK.OL)

25.91% Forward Dividend Yield and 19.37% Return On Equity

Elkem ASA engages in the provision of advanced material solutions worldwide. It operates through three segments: Silicones, Silicon Products, and Carbon Solutions. The company offers silicones polymers, including silicone oils, compounds, emulsions, grease, and resins, as well as chlorosilanes, heat cured rubber silicone, liquid silicone rubber, and RTV-1 and RTV-2 silicones. It also provides silicon-based materials comprising silicon, silicon powder/micronized silicon, silica fume/ micro-silica, ferrosilicon, and grain refiners. In addition, the company offers foundry alloys, such as preconditioners, recarburizers, conditioners, nodularizers, inserts, and inoculants; and carbon-based materials comprising carbon electrodes, furnace tapping materials, electrode paste, ramming paste, prebaked electrodes, and furnace lining materials, as well as polymer additives, and oilfield and refractories specialty products. It offers its products to electronics, aerospace, healthcare, personal care, packaging, airbag coating, chemicals, aluminium, electronics, automotive, specialty steel, solar, construction, refractories, oil and gas, ferroalloys, silicon, and aluminium industries. The company was founded in 1904 and is headquartered in Oslo, Norway. Elkem ASA operates as a subsidiary of Bluestar Elkem International Co., Ltd. S.A.

Earnings Per Share

As for profitability, ELKEM has a trailing twelve months EPS of kr-0.8.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.37%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is a negative 83.5% and a negative 31.2%, respectively.

More news about ELKEM.

2. SOLVAC NOM(RETAIL) (SOLV.BR)

5.7% Forward Dividend Yield and 4.21% Return On Equity

Solvac S.A. operates as an advanced materials and specialty chemicals company in Belgium. It offers specialty polymers, composite materials, soda ash, peroxides, silica, and coatis. The company was incorporated in 1983 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, SOLVAC NOM(RETAIL) has a trailing twelve months EPS of €5.96.

PE Ratio

SOLVAC NOM(RETAIL) has a trailing twelve months price to earnings ratio of 17.28. Meaning, the purchaser of the share is investing €17.28 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.21%.

More news about SOLVAC NOM(RETAIL).

3. CORTICEIRA AMORIM (COR.LS)

4.44% Forward Dividend Yield and 11.55% Return On Equity

Corticeira Amorim, S.G.P.S., S.A. manufactures and sells cork and cork related products in Europe, the United States, Portugal, Australasia, and Africa. The company operates through Amorim Florestal, Amorim Cork, Amorim Cork Flooring, Amorim Cork Composites, Amorim Cork Insulation, and Corticeira Amorim and Others segments. It offers raw materials for cork and agroforestry markets; and cork stoppers for still and sparkling wine, spirit, beer, and cider industries. The company also provides cork composite solutions for use in various applications, such as aerospace, mobility, energy, sealing, construction, sports and recreational surfaces, maritime, flooring, home, office and leisure goods, footwear, toys, and footwear. In addition, it offers insulation cork materials for use in sustainable construction/insulation, and interior and exterior designing; and flooring solutions to floor and wall coverings markets. The company was founded in 1870 and is headquartered in Mozelos, Portugal. Corticeira Amorim, S.G.P.S., S.A. operates as a subsidiary of Amorim Investimentos e Participações, S.G.P.S., S.A.

Earnings Per Share

As for profitability, CORTICEIRA AMORIM has a trailing twelve months EPS of €0.61.

PE Ratio

CORTICEIRA AMORIM has a trailing twelve months price to earnings ratio of 14.62. Meaning, the purchaser of the share is investing €14.62 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.55%.

Moving Average

CORTICEIRA AMORIM's value is below its 50-day moving average of €9.53 and below its 200-day moving average of €9.38.

Volatility

CORTICEIRA AMORIM's last week, last month's, and last quarter's current intraday variation average was a negative 0.28%, a negative 0.26%, and a positive 0.92%.

CORTICEIRA AMORIM's highest amplitude of average volatility was 0.96% (last week), 0.94% (last month), and 0.92% (last quarter).

Volume

Today's last reported volume for CORTICEIRA AMORIM is 19375 which is 64.79% below its average volume of 55028.

Sales Growth

CORTICEIRA AMORIM's sales growth is 0.2% for the current quarter and 8.5% for the next.

More news about CORTICEIRA AMORIM.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com